JAMMI最新文献_第8页

A case of mumps-associated myocarditis 流行性腮腺炎相关心肌炎1例

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2017-0008

R. Leblanc, Sadiq Al Lawati, S. Lother, R. Lester, A. Jassem

引用次数: 0

Epidemiology and treatment of carbapenemase-producing Enterobacteriaceae bacteremia in a community hospital setting 社区医院中产碳青霉烯酶肠杆菌科菌血症的流行病学和治疗

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2017-0010

Sheena Pang, Ehsan Haghshenas, David Richardson, M. Baqi

{"title":"Epidemiology and treatment of carbapenemase-producing Enterobacteriaceae bacteremia in a community hospital setting","authors":"Sheena Pang, Ehsan Haghshenas, David Richardson, M. Baqi","doi":"10.3138/JAMMI.2017-0010","DOIUrl":"https://doi.org/10.3138/JAMMI.2017-0010","url":null,"abstract":"Background: Carbapenemase-producing Enterobacteriaceae (CPE) infections are a rapidly evolving global threat. With bacteremia mortality rates exceeding 40%, limited consensus exists regarding optimal antimicrobial treatment. Objectives: To characterize our institution’s CPE bacteremia population and describe the antimicrobial regimens used for treatment. Methods: A dual-centre retrospective chart review was conducted of adult CPE bacteremia patients admitted between January 1, 2010 and April 30, 2017. Baseline demographics included out-of-country hospitalization, causative organism, and susceptibilities. Treatment details included antimicrobial agent, dosing regimen, and use of monotherapy or combination therapy. Clinical outcomes included 30-day all-cause mortality and 30-day re-admission rates. Results: Thirteen cases of CPE bacteremia were reviewed. Nine patients had previously been hospitalized in the Indian subcontinent. Twelve isolates produced the New Delhi metallo-beta-lactamase-1 (NDM-1). All isolates were sensitive (n = 8) or intermediate (n = 5) to tigecycline. An equal number of cases were treated with monotherapy (n = 6) and combination therapy (n = 6). The most commonly prescribed antimicrobials were colistin (n = 7) and tigecycline (n = 8). The overall 30-day mortality and re-admission rates were 54% (7/13) and 50% (3/6), respectively, although the effect of potential confounders such as causative CPE, monomicrobial or polymicrobial infection, or delay in therapy were not considered. Conclusions: This study highlights the largest Canadian CPE bacteremia cohort to date. CPE bacteremia most commonly occurred in patients with prior hospitalization in the Indian subcontinent. Based on our antimicrobial susceptibility testing results, tigecycline may have a role as part of empiric therapy at our institution.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41813835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of Lemierre’s syndrome complicated by clival osteomyelitis and bilateral cranial nerve XII palsy Lemierre综合征并发斜坡骨髓炎和双侧颅神经第十二麻痹1例

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2018.06.15

D. Smyth, J.L.G. Mowat, M. Rigby

引用次数: 1

A clinical vignette on Raoultella planticola bacteremia 植物拉乌尔氏菌菌血症的临床观察

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2017-0005

Jessica Huynh, J. Fleet, Jo-Hua Peng, J. La, Ahraaz Wyne

引用次数: 1

Evaluation of a clinic-based quality structure for Special Access Programme medicines to treat parasitic infections 评估以诊所为基础的用于治疗寄生虫感染的特别获取规划药品质量结构

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2017-0003

Rochelle G. Melvin, C. Thompson, S. Peermohamed, M. Klowak, S. Klowak, A. Boggild

{"title":"Evaluation of a clinic-based quality structure for Special Access Programme medicines to treat parasitic infections","authors":"Rochelle G. Melvin, C. Thompson, S. Peermohamed, M. Klowak, S. Klowak, A. Boggild","doi":"10.3138/JAMMI.2017-0003","DOIUrl":"https://doi.org/10.3138/JAMMI.2017-0003","url":null,"abstract":"Background: Frequently used drugs in our unit are only available through Health Canada’s Special Access Programme (SAP) or a compounding pharmacy. A tracking system was implemented to evaluate the turnaround time (TAT) and success rate of SAP applications for parasitic infections. Methods: We undertook a retrospective review of SAP logs from 2013 to 2015 inclusive, with outcomes of TAT and initial application success rates over time. Analyses were stratified by drug indication. Results: The mean TATs for all indications from 2013 to 2015 were 9.02 (SD 10.11) days, 7.04 (SD 7.6) days, and 7.25 (SD 8.97) days, respectively (p = 0.48). First-time success rates for ivermectin from 2013 to 2015 were 96%, 84%, and 71%, respectively. First-time success rates for albendazole from 2013 to 2015 were 74%, 60%, and 63%, respectively. In 2013, 14% (6/44) of initial SAP requests received an incomplete notification compared with 25% (14/57) and 32% (25/78) in 2014 and 2015, respectively (p = 0.08). Conclusions: Timely initiation of antihelminthic therapy is critical to reducing the risk of adverse clinical outcomes and a decreased quality of life from parasitic infections such as strongyloidiasis. Our findings document a prolonged TAT of non-formulary medications used to treat common helminthiases in Canada.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2017-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45919358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Antimicrobial resistance in conflicts 冲突中的抗菌素耐药性

JAMMI Pub Date : 2018-08-20 DOI: 10.3138/JAMMI.2018.05.15

L. Haraoui, L. Valiquette, K. Laupland

引用次数: 1

Imported pulmonary melioidosis in Québec, Canada 加拿大quacimubec输入性肺类鼻疽病

JAMMI Pub Date : 2018-06-01 DOI: 10.3138/JAMMI.2017.12.12

Leighanne O. Parkes, M. Cheng, S. Bekal, K. Antonation, G. Zaharatos

引用次数: 0

Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection 加拿大医学微生物学和传染病协会艰难梭菌感染治疗实践指南

JAMMI Pub Date : 2018-06-01 DOI: 10.3138/JAMMI.2018.02.13

V. Loo, I. Davis, J. Embil, G. Evans, S. Hota, Christine H. Lee, T. Lee, Y. Longtin, T. Louie, P. Moayyedi, S. Poutanen, A. Simor, T. Steiner, N. Thampi, L. Valiquette

{"title":"Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection","authors":"V. Loo, I. Davis, J. Embil, G. Evans, S. Hota, Christine H. Lee, T. Lee, Y. Longtin, T. Louie, P. Moayyedi, S. Poutanen, A. Simor, T. Steiner, N. Thampi, L. Valiquette","doi":"10.3138/JAMMI.2018.02.13","DOIUrl":"https://doi.org/10.3138/JAMMI.2018.02.13","url":null,"abstract":"McGill University Health Centre, McGill University, Montréal, Québec; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia; Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba; Kingston Health Sciences Centre, Queen’s University, Kingston, Ontario; University Health Network, University of Toronto, Toronto, Ontario; St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario; Jewish General Hospital, McGill University, Montréal, Québec; Peter Lougheed Hospital, University of Calgary, Calgary, Alberta; Health Sciences Centre, McMaster University, Hamilton, Ontario; Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario; Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia; Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2018.02.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43933743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30

Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada 明智地选择加拿大——医学微生物学前五名:加拿大医学微生物学和传染病协会(AMMI)的官方立场声明

JAMMI Pub Date : 2018-06-01 DOI: 10.3138/JAMMI.2018.02.08

J. Leis, T. Hatchette, W. Ciccotelli, P. Daley, L. Goneau, D. Gregson, Shobhana Kulkarni, V. Loo, Phillipe Lagacé-Wiens, C. Lowe, L. Matukas, D. Roscoe, E. Rubin, W. Gold

{"title":"Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada","authors":"J. Leis, T. Hatchette, W. Ciccotelli, P. Daley, L. Goneau, D. Gregson, Shobhana Kulkarni, V. Loo, Phillipe Lagacé-Wiens, C. Lowe, L. Matukas, D. Roscoe, E. Rubin, W. Gold","doi":"10.3138/JAMMI.2018.02.08","DOIUrl":"https://doi.org/10.3138/JAMMI.2018.02.08","url":null,"abstract":"Background: Choosing Wisely Canada is a forum for health care professional societies to lead system change through identification and reduction of low-value practices. Microbiologic investigations are frequently overused and may contribute to unnecessary health care expenditures as well as patient harm. Methods: A Choosing Wisely Canada top five list in medical microbiology was developed by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada through broad consultation of its members. Following an electronic survey of members, recommendations were developed and ranked by a working group, then further narrowed during a national open forum using the modified Delphi method. Feedback was solicited through an online forum prior to dissemination. Results: The top five declarative statements in medical microbiology are: ( 1 ) Don’t collect urine specimens for culture from adults who lack symptoms localizing to the urinary tract or fever, ( 2 ) Don’t routinely collect or process specimens for Clostridium difficile testing when stool is non-liquid or if the patient has had a prior nucleic acid amplification test result within the past 7 days, ( 3 ) Don’t obtain swabs from superficial ulcers for culture, ( 4 ) Don’t routinely order nucleic acid amplification testing on cerebrospinal fluid in patients without a compatible clinical syndrome, and ( 5 ) Don’t routinely obtain swabs during surgical procedures when fluid and/or tissue samples can be collected. Conclusions: This Choosing Wisely list represents a launching point to reduce low-value practices in microbiology. Strong implementation science around these statements will be needed to improve the value of microbiology testing in Canada.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2018.02.08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47450491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Evaluation of the safety of piperacillin/tazobactam use in admitted pediatric patients with cystic fibrosis 评价哌拉西林/他唑巴坦在儿科囊性纤维化住院患者中的安全性

JAMMI Pub Date : 2018-06-01 DOI: 10.3138/JAMMI.2017-0012

Natalie Mathews, S. Zayed, Nicholas Winters, L. Lands, A. Shapiro, J. Cote, C. Quach

{"title":"Evaluation of the safety of piperacillin/tazobactam use in admitted pediatric patients with cystic fibrosis","authors":"Natalie Mathews, S. Zayed, Nicholas Winters, L. Lands, A. Shapiro, J. Cote, C. Quach","doi":"10.3138/JAMMI.2017-0012","DOIUrl":"https://doi.org/10.3138/JAMMI.2017-0012","url":null,"abstract":"Background: Piperacillin/tazobactam (PT) is a first-line antibiotic for Pseudomonas aeruginosa (PsA) respiratory infections in patients with cystic fibrosis (CF), but increased adverse reactions (ARs) have been reported in these patients. We aimed to determine the incidence of and risk factors for ARs to PT within the pediatric CF population. Methods: We conducted a retrospective analysis of CF patients at a pediatric tertiary care centre who had received PT and compared ARs associated with PT versus other antipseudomonal antibiotics. Results: Of the 26 patients who received PT, the PT AR prevalence was n=7 (27%); 3 patients developed fever and rash, 2 had only fever, 1 had only rash, and 1 had fever, rash, and severe neutropenia. The following variables were associated with fever following PT administration: younger age (8.46 versus 13.15 years, p=0.02), fewer previous admissions for CF pulmonary exacerbation (1.67 versus 7.25, p=0.03), and increased PT dose (386.37 versus 270.73 mg/kg/day, p=0.02). Younger age was also associated with increased overall AR to PT (9.6 versus 13.3 years, p=0.04). Increased PT dose was associated with fever (OR 1.02 (1.00–1.05), p=0.03) and with overall reactions (OR 1.01 (1.00–1.02), p=0.03). Comparing incidence rates of ARs following PT and ticarcillin/clavulanate resulted in a trend toward increased relative reaction to PT, but confidence intervals (CIs) were not significant. Conclusions: We found a high AR rate associated with PT, and an association between increased dose and fever and overall ARs.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46774254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1